Neuromodulation : journal of the International Neuromodulation Society
-
Objectives Intraspinal drug delivery via indwelling pump is an effective means of treating refractory pain. Before a patient is selected for pump implantation, an intraspinal drug delivery trial must be performed to establish side-effects and efficacy profiles. No consensus protocol currently exists for such trials. ⋯ Nearly half (45%) of the respondents use the continuous intrathecal infusion technique to select patients for permanent implants. Conclusions Trial practices vary widely in terms of patient selection, medication choice, technique, and efficacy evaluation. We hope that our findings will encourage a concerted effort to evaluate existing trial protocols in order to establish a reliable standard of care.
-
Objectives To retrospectively analyze by indices of success, patients with chronic complex pain, including, axial low back pain, receiving dual spinal cord stimulation (SCS) systems. Methods Eighteen patients with dual spinal cord stimulators have been retrospectively and nonrandomly analyzed. The preponderance of patients in our study group had failed back surgery syndrome (FBSS). ⋯ Thirteen (81%) patients with dual lead SCS therapy were willing to repeat the SCS implant procedure. Complications occurred in 43.7%. Conclusions Dual spinal cord stimulation is appropriate and efficacious for treating complex pathology and complex pain that including pain of the low, axial back.
-
Sjögren syndrome is a chronic autoimmune disease. This disease mainly involves salivary and lacrimal glands, although it may also involve the musculoskeletal, respiratory, gastrointestinal, renal, hepato-biliary, hematological, neurological, vascular, or both systems. Small vessel disease may appear in up to 30% of the cases. ⋯ In our pain unit, a percutaneous posterior spinal cord stimulator (SCS) was placed. SCS clinically reduced her pain by 90% and helped to improve her quality of life and significantly reduced her intake of analgesics. We conclude spinal cord stimulation may be a good alternative to conservative therapies in patients with vasculitis of Sjögren syndrome.
-
Objective The purpose of this study was to test if the F-response can be repressed volitionally. Normally, the F-response is used for clinical diagnostics but it also has an important influence on the design of a neural prosthesis involving functional electrical stimulation (FES) and the use of volitional myoelectric signal (MES) for control. Methods Ten neurologically normal subjects were trained to reduce the level of the F-response from the anterior tibial muscle. ⋯ From the first to the last session of a trial, the change was found not significant. Conclusion The level of the F-response may change locally, but there is no indication that a subject can volitionally learn to repress the response, even when given feedback information about the actual level. Therefore the F-waves in the myoelectric signal from a stimulated muscle has to be accounted for when designing devices using a stimulated muscle response for myoelectric control such as eliminating the F-interval from the recorded signal.